Skip to main content

Table 2 Distribution of baseline characteristics according to treatment outcome

From: Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern

  Early deterioration (7 patients) Non-early deterioration (26 patients) p value
Baseline electrophysiological parameters    
Pattern of demyelination, number (%)    
  Pure focal 5 (71%) 5 (19%) 0.02
  Non-Focal 2 (29%) 21 (81%)  
CMAP amplitude median nerve (median, mV) 10 (6) 6 (5) 0.29
MNCV arms (mean, m/s) 49.7 (10) 39.6 (12) 0.08
MNCV legs (mean, m/s) 39.6 (3) 37.1 (12) 0.53
Number of CB per examined segments (mean) 0.31 (0.2) 0.36 (0.2) 0.70
Sensory involvement severity, number (%)    
  Normal/minor 4 (57%) 6 (23%) 0.19
  Moderate/severe 3 (43%) 20 (77%)  
SNAP amplitude median nerve (median, μV) 15 (13) 7 (10) 0.13
SNCV median nerve (mean m/s) 52.6 (7) 40.8 (12) 0.02
Baseline clinical parameters    
MRC sum scores (mean) 49.9(2) 50.2 (5) 0.77
Grip strength (median, kPa) 102 (180) 88 (64) 0.37
INCAT sensory sum score (median) 6(7) 9(7) 0.56
INCAT disability score (median) 3(2) 4(3) 0.42
Rivermead Mobility Index (median) 12(3) 12(6) 0.91
  1. Legend: Abbreviations: MNCV motor nerve conduction velocity, CB conduction block (definite and probable summated), MRC Medical Research Council, INCAT inflammatory neuropathy cause and treatment. Numbers in brackets represent the standard deviation for mean values or interquartile range for median values.